Fig. 10

Treatment with TXNIP/NLRP3/Caspase-1 pathway inhibitors attenuates DOX-induced cardiotoxicity in PDX models. a–c Western blot analysis of target proteins in DOX (1 μM), 24 h)-treated adult murine ventricular cardiomyocytes (AMVCs) co-cultured with 4T1 cells upon VX765, MCC950, or SRI-37330 treatment. d Schematic diagram showing the treatment protocol of PDX model mice with DOX and inhibitor. e–i Cardiac function parameters including E/A ratio, -E/E′ ratio, left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), and plasma BNP levels. j Representative image of H&E staining. Scale bar: 50 μm. k Quantification of cardiomyocyte vacuolation. Scale bar: 50 μm. l Representative image of Sirius red staining. Scale bar: 50 μm. m Quantification of cardiac fibrosis area. n Representative image of wheat germ agglutinin (WGA) staining. o Quantification of cardiomyocyte size. “i.p.(q.o.d.)” indicates intraperitoneal injection every other day; “p.o.(q.d.)” indicates oral administration once daily, “E” indicates early diastolic transmitral flow velocity, “E′” indicates early diastolic mitral annular velocity, “A” indicates late (atrial) diastolic transmitral flow velocity, and “DOX” indicates doxorubicin. The schematic diagram part was created using SMART - Servier Medical Art by Servier. Data are presented as means ± SD